United States companies publish curable cancer drug

【-News 】 United States aarni RAM biotechnology company recently announced that they found a cure for all cancers of new drugs, the first batch of accepted clinical trials of 19 advanced liver cancer patients have a greater improvement. Moreover, the company stated that, over time, this drug is even possible to cure all diseases.

The first patients were well received by

Last April, 19 receive chemotherapy but no improvement of hepatic patients start taking this new named ALN-VSP. After taking the first dose of few weeks, the drug has clearly begun blocking tumor producing its own growth need protein.

In June of this year, Arni RAM company that, through the "wake up" the human body itself a seldom-used immune defense system, a successful cut liver cancer patients ALN-VSP in vivo tumor blood flow to 62%. In the treatment of liver cancer, traditional medicines generally use the Elimination of pathogenic proteins and RNA interference by ALN-VSP (RNAi) therapy directly to the block cells causing proteins.

Awaken the body's own defense mechanism

Scientists in the study also found ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) link between a wonderful — if DNA on protein is a drawing, the RNA is the ability to issue instructions to contractors. RNA genes on the DNA replication into a single chain of messenger RNA, which it then passes the information to cells produce protein.

In 1998, scientists discovered the RNA interference (RNAi) mechanism, the original bio is using this system to identify and destroy the viral double-stranded RNA and RNA viruses Messenger. The researchers found, will be a short double-stranded RNA into cells that can trigger this buried in the body of the ancient mechanism for RNAi play again to halt the production of specific proteins.

From that perspective, it can be said that RNAi has cured including cancer, many diseases, these diseases are usually characterized by a lesion cell protein produced excessive common. In theory, the manipulation of RNAi to kill protein is not difficult. For example, it contains within ALN-VSP synthesis of double-stranded RNA, and liver tumors for encoding two proteins of messenger RNA that match, the two proteins are the promotion of tumor blood vessel growth of vascular endothelial growth factor (VEGF) and accelerated tumor cells quickly split spindle driven protein (KSP).

Synthesis of double-stranded RNA into liver cells, the body of the RNAi mechanism will destroy the synthesis of RNA and any matching, and tumor growth related messenger RNA, block continues to produce proteins, thus enabling the growth of tumor stopped.

Expected to be a "one-size-fits-all"

In addition to the application in the field of cancer, it can attack a single gene technology has in other medical field set off a wave of RNAi therapeutics. Currently, Arni RAM company has this kind of therapy for Huntington's dance, retinal macular degeneration, muscle atrophy, and study AIDS and other diseases.

California renowned molecular geneticists John · Rossi, RNAi therapeutics is expected within two years to mature. Since the first test is quite good, ALN-VSP is expected to become the first theory based on RNAi and drug to market. Rossi said: "I think the RNAi therapy on all diseases are valid. ”